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Establishment of viral persistence in cell culture has previously led to the selection of mammalian
reovirus mutants, although very few of those have been characterized in details. In the present study,
reovirus was adapted to Vero cells that, in contrast to classically-used L929 cells, are inefficient in
supporting the early steps of reovirus uncoating and are also unable to produce interferon as an antiviral
response once infection occurs. The Vero cell-adapted reovirus exhibits amino acids substitutions in
both the σ1 and μ1 proteins. This contrasts with uncoating mutants from persistently-infected L929
cells, and various other cell types, that generally harbor amino acids substitutions in the σ3 outer capsid
protein. The Vero cell-adapted virus remained sensitive to an inhibitor of lysosomal proteases;
furthermore, in the absence of selective pressure for its maintenance, t he virus  has partially lost its
ability to resist interferon. The positions of the amino acids substitutions on the known protein
structures suggest an effect on binding of the viral σ1 protein to the cell surface and on μ1 disassembly

















Mammalian reovirus is currently under clinical study as an oncolytic virus for the treatment of 
various cancers in humans (recently reviewed and discussed by: Black and Morris, 2012; Harrington
et al., 2010; Kelly et al., 2009; Lal et al., 2009). The rationale behind this approach is the ability of 
reovirus to preferentially infect and destroy Ras-transformed/cancer cells compared to parental or so-
called “normal” cells (Coffey et al., 1998; Roner and Mutsoli, 2007; Smakman et al., 2005; Strong 
et al., 1996, 1998). However, the exact mechanism underlying this preferential replication is still 
incompletely understood. Various observations initially suggested that inhibition of the interferon 
response by activation of the Ras signaling pathway is responsible for increased efficiency of reovirus 
infection (Park et al., 2010; Rudd and Lemay, 2005; Shmulevitz et al., 2010; Strong et al., 1998). 
However, it is likely that better viral uncoating is also involved in increased efficiency of early steps of 
the viral multiplication cycle in transformed cells (Alain et al., 2007; Lemay et al., 2007; Marcato et 
al., 2007).
Reovirus capsid is made of two concentric protein layers and is incompletely uncoated upon viral
entry by endocytosis (reviewed by: Danthi et al., 2010; Guglielmi et al., 2006). The outer capsid 
proteins are partially removed by cellular proteases such as lysosomal cathepsins (L, B or S) (Ebert et 
al., 2002; Golden et al., 2004; Johnson et al., 2009), elastase (Golden and Schiff, 2005) or 
transmembrane serine proteases (Nygaard et al., 2012). Partial removal of outer capsid proteins 
generates infectious subviral particles (ISVPs) that are able to cross endosomal membranes allowing 
the release of viral particles in the cytoplasm. As an alternative mode of penetration, ISVPs could be 
generated by extracellular proteases, apparently allowing direct penetration of viral particles through 
the plasma membrane. In fact, this is probably the major mode of infection in the gastrointestinal tract 
where proteases are abundant (Amerongen et al., 1994; Bass et al., 1990; Bodkin et al., 1989; 
reviewed by: Schiff et al., 2007).
Although this may not be sufficient to completely explain the preferential infection of 
transformed cells, an increased level of proteases, protease activity, or changes in subcellular 
localization of these enzymes, is a known effect of cellular transformation. A correlation between Ras 
transformation and the level or activity of cathepsins was reported in the past, as well as a redistribution
of the enzyme, allowing either secretion or increased presence at the membrane surface (Cavallo-

































and Kominami, 1995; Joseph et al., 1987; Kim et al., 1998; Urbanelli et al., 2010). The level or 
localization of proteases is thus an important factor to determine host-cell permissivity to reovirus and 
it appears that viral uncoating is often a limiting factor in different cell lines or cell types such as MEF 
cells (primary murine embryo fibroblasts: Golden et al., 2002; Nygaard et al., 2012), MEL cells 
(murine erythroleukemia cells: Wetzel et al., 1997a), NIH-3T3 cells (immortalized murine embryo 
fibroblasts: Alain et al., 2007; Marcato et al., 2007), SC1 cells (murine feral embryo fibroblasts: 
Lemay, unpublished data), U118 cells (human glioblastoma cells: Alain et al., 2007) or Vero cells 
(african green monkey kidney cells: Golden et al., 2002).
Despite the fact that reovirus is naturally “oncolytic” and able to discriminate between parental 
and transformed/cancer cells, without prior genetic manipulation, it is generally believed that it could 
be adapted to further optimize its oncolytic ability (Kim et al., 2007; Rudd and Lemay, 2005; 
Shmulevitz et al., 2012; van den Wollenberg et al., 2009, 2012). It has been shown that the 
establishment of persistent reovirus infection leads to a gradual virus-cell co-evolution, resulting in an 
increased resistance of the cells to the wild-type parental virus while the virus develops an increased 
ability to infect these cells; this viral adaptation allows maintenance of the persistent state by 
continuous re-infection (reviewed by: Dermody, 1998). However, the nature of mutations present on 
the viruses resulting from this co-evolution was clearly documented only in murine L929 fibroblasts 
and results from amino acids substitution(s) in the surface-exposed lobe of the σ3 outer capsid protein, 
thus increasing its sensitivity to proteases and favoring viral uncoating under conditions where 
proteases are present in limited amount (Baer and Dermody, 1997; Wetzel et al., 1997b). It remains 
to be determined if viruses selected in different cell types will be similarly altered in their ability to be 
uncoated and if similar amino acids substitution(s) will be selected independently of cell types. It was 
recently suggested that it is the case, although amino acids substitutions in σ1 were also observed (Kim
et al, 2011). However, the exact role of these amino acids substitutions was not directly established nor 
further examined. Furthermore, a deletion in σ1, the outer capsid cell binding protein (reviewed by: 
Danthi et al., 2010), selected during persistence in one cell line, was also shown to attenuate the virus 
while having a limited effect on infection of cancer cells, supporting the idea that viral persistence 
could be used to select for viruses that are better adapted as oncolytic agent (Kim et al., 2011).
In the present study, the reovirus serotype 3 Dearing was adapted to Vero cells by establishment 
of viral persistence. These cells were chosen since they differ from L929 cells by their lack of 

































inefficient at uncoating the virus, likely due to reduced levels of lysosomal uncoating proteases 
(Golden et al., 2002). The Vero cell-adapted virus (VeroAV) infects Vero cells better than the original 
wild-type virus in the absence of chymotrypsin and forms plaques under these conditions, in contrast to
the wild-type virus, while remaining sensitive to an inhibitor of lysosomal cathepsins; this contrasts 
with uncoating mutants selected during viral persistence in L929 cells (Baer and Dermody, 1997; 
Wilson et al., 2002). Furthermore, in the absence of selective pressure for the maintenance of a certain 
level of resistance, the virus has apparently lost part of its ability to resist interferon. Sequencing of the 
genes encoding the three outer capsid proteins revealed the absence of amino acids substitution in the 
σ3 protein while two amino acids changes were found in the σ1 protein, including one at a location 
consistent with an increased binding to host cell-surface sugar moieties (Reiter et al., 2011). In 
addition, two amino acids substitution were also found in μ1 at positions that could affect outer capsid 
structure or disassembly (Zhang et al., 2005) and possibly indirectly affect interferon resistance. 
Altogether these results support the idea that adapting the virus to different cell types could generate 
novel viruses to be used as alternatives to the wild-type virus in future oncolytic applications.
2. Materials and methods
2.1. Cell lines and viruses
L929 mouse fibroblasts and Vero cells (African green monkey kidney cells) were originally 
obtained from the American type culture collection (ATCC); all cells were grown in minimal Eagle 
medium (MEM) with 5% fetal bovine serum, 1% L-glutamine and 1% P/S from commercial stock 
solutions (Wisent Bioproducts).
Wild-type reovirus laboratory stock was derived from a pure plaque of reovirus type 3 Dearing 
(T3/Human/Ohio/Dearing/55). The original inoculum was obtained from the American Type Culture 
Collection (ATCC). A high-passage stock of the virus was obtained by first infecting a semi-confluent 
100 mm petri dish of L929 at a MOI of 80; after complete cell lysis, one-twentieth of the cell lysate 
was used to infect a similar dish; this procedure was repeated each 48 h up to ten passages of the virus. 
2.2. Antibodies

































(Virgin et al., 1991) and were obtained from Kevin Coombs (University of Manitoba). Hybridoma 
cells were grown in MEM for suspension culture with 10% fetal bovine serum, proline (20 μg/ml) and 
β-mercaptoethanol (50 μM) and antibodies were recovered as previously described (Brochu-
Lafontaine and Lemay, 2012). The FITC-conjugated goat antireovirus antibody was obtained from 
Accurate Chemical & Scientific Corporation (catalog # YV0031-10).
2.3. Determination of virus titer.
Virus titers were determined by plaque assay on Vero cells in the presence of chymotrypsin 
(Sigma Type I-S from bovine pancreas) at 10 μg/ml, as previously described (Brochu-Lafontaine and 
Lemay, 2012).
2.4. Quantitation of reovirus-infected cells by FACS
To compare the percentage of infected cells, cells were infected at the same multiplicity of 
infection and analyzed by FACS. Cells from a 6-wells plate were collected by treatment with 6 mM 
EGTA (Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid) at 37°C for 10 min, 24 h 
post-infection, and resuspended in 1 ml of EMEM containing 5% fetal bovine serum before recovery 
by centrifugation at 4°C for 5 min at 1500 x g. The pellet was resuspended in 0.25 ml of 
Cytofix/Cytoperm (Becton Dickinson) on ice with gentle agitation and left 20 min before mild 
centrifugation in microplates at 350 x g. Cells were then resuspended in the 0.25 ml Perm Wash buffer 
(Becton Dickinson) centrifuged again and resuspended in 0.035 ml of buffer to which 0.015 ml of 
FITC-conjugated antireovirus antibody was added. Following 30 min on ice with occasional gentle 
agitation, cells were pelleted, washed twice in buffer, and fixed with 4% paraformaldehyde before 
being analyzed on a BD FACSCalibur cytofluorometer (Becton Dickinson).
2.5. Immunoblotting
Infected cells were recovered by scraping in small volume of medium and centrifuged in an 
Eppendorf tube at 13 000 x g for 5 min at 4°C. Cell pellets corresponding to a 60 mm-diameter petri 
dish were resuspended in 45 μl of permeabilization buffer (Tris-HCl 10 mM pH 7.5, 1 mM EDTA, 150 
mM NaCl, 1% Nonidet P-40) and left on ice for 5 min before centrifugation at 13 000 x g  for 1 min in 
an Eppendorf centrifuge at 4°C. Proteins were analyzed by SDS-PAGE and immunoblotting. 

































TBS (Tris-HCl 10 mM pH 7.5, 150 mM NaCl) and  incubated for 1 h at room temperature with the 
anti-ơ3 and anti-μ1 monoclonal antibodies. Antibodies in tissue culture medium were diluted with an 
equal volume of TBS containing the blocking agent and directly used. The diluted antibody solution 
was recovered and kept at 4ºC with 1 mM sodium azide to be used up to 10 times. Membranes were 
washed in TBS containing 1% Tween-20. Revelation was done using peroxydase-conjugated secondary
anti-mouse IgG antibody and chemiluminescent substrate, as recommended by the manufacturer 
(Pierce SuperSignal West Dura Extended Duration Substrate). Images were obtained using a Typhoon 
Trio™ imager (GE Healthcare Life Sciences).
2.6. Determination of viral sensitivity to uncoating inhibitors
To determine the sensitivity of wild-type and VeroAV to either an inhibitor of endosomal 
acidification or of lysosomal protease, L929 cells were treated with either 5 mM of ammonium chloride
(at 5 mM) or E64 (L-transepoxysuccinyl-leucylamido-[4-guanidino]butane; Sigma-Aldrich) at 50 or 
100 μM; control cells were left untreated. Control or treated cells were then infected at a multiplicity of
infection of 2 PFU/cell and incubated for 24 h in the presence of the inhibitor. Petri dishes (cells and 
medium) were frozen at -80°C, 24 h post-infection, and subjected to three cycles of freeze-thaw before 
virus titration by plaque assay on chymotrypsin-treated Vero cells.
2.7. Induction of and sensitivity to interferon.
For the detection of induced interferon, L929 cells were infected with either wild-type or VeroAV
at a multiplicity of infection of 5 and the supernatant was recovered 12 h post-infection. Recovered 
supernatant was then passed through a Vivaspin 100 000 molecular weight cutoff filter (Sartorius) to 
remove infectious reovirus. Virus-free supernatant was then used in encephalomyocarditis titration 
assay by determination of the “tissue culture infectious dose 50%” ( TCID50) on L929 cells, as 
previously described (Sandekian et al., 2013).
To determine virus' sensitivity to interferon, L929 cells in 96-wells plates were pre-treated with 
500 or 100 IU/ml of murine interferon-β (PBL interferon source) and used in TCID50  assay of either 
wild-type or VeroAV, as previously described (Danis et al., 1997). Number of infected wells was 
determined by direct examination using phase-contrast microscopy.

































Virus stocks were used to infect L929 cells in 10 cm-diameter petri dishes at a MOI of 10 
PFU/cell. Cells and medium were recovered at 24-30 h post-infection, at which time most cells were 
lysed. Following two cycles of freeze-thaw (-80ºC to room temperature), the lysate was extracted once 
with one-fourth volume of freon (1,1,2-Trichloro-1,2,2,-trifluoroethane, Mallinckrodt Chemicals). After
10 min of centrifugation at 7 000 g in a Sorvall SS-34 rotor at 4ºC (in Corex 15 ml tubes), supernatant 
was recovered and overlayed on a 1ml cesium chloride cushion at a density of 1.3 g/ml for 
ultracentrifugation in a 70Ti rotor at 250 000 g for 1 h at 4ºC. Virus pellet was recovered in 400 μl of 
TE buffer (10mM Tris-HCl pH 7.5, 1mM EDTA) before addition of 0.2% SDS followed by phenol-
chloroform extraction and ethanol precipitation of viral double-stranded RNA. The RNA was denatured
at 95ºC for 5 min and cooled rapidly on ice. Reverse transcription was done on both strands using one-
fourth of the RNA and oligonucleotides specific for each strand at both ends of the gene to be 
sequenced. These reverse transcription reactions were done with MLV reverse transcriptase was for 1 h 
at 37ºC, as recommended by the manufacturer (Roche). One-fifth of the reverse transcriptase reaction 
was then used in a PCR reaction with the same two oligonucleotides for 40 cycles using FastStart 
protocol, as recommended by the manufacturer (Roche). The PCR fragment was then purified using the
Qiaquick PCR purification kit as recommended by the manufacturer (Qiagen) and sequenced by 
automated DNA sequencing (Applied Biosystems 3730 DNA Analyzer) in the sequencing service of 
Institut de recherche en immunologie et cancérologie (IRIC) of Université de Montréal.
The oligonucleotides used for S4 RT-PCR were GCTATTTTTGCCTCTTCCCAGACG 
(nucleotide 1 to 24) and GATGAATGAAGCCTGTCCCACGTC (nucleotide 1173 to 1196 on the 
complementary strand); sequencing was done using the same two primers as well as 
CAAGTTGGACAGATCCTTTGCAG (nucleotide 472 to 494) and 
GGGTATCAAGTCGGATGAGTCGA (nucleotide 553 to 575 on the complementary strand).
For the M2 gene two separate RT-PCR fragments were used to cover the whole gene: 
oligonucleotides  GCTAATCTGCTGAGCGTTACTCTG (nucleotide 1 to 24) and 
CCGATCTGTGAAGCAGCAGTCC (nucleotide 1267 to 1288 on the complementary strand) were 
used together to amplify the 5' portion of the gene while oligonucleotide 
CTGGACCAAATCGCTCCGATGCGG (nucleotide 1137 to 1160) and   
GATGATTTGCCTGCATCCCTTAACCCCG (nucleotide 2176 to 2203 on the complementary strand) 
were used to amplify the 3' portion. Sequencing was done with the same primers and with primers  

































(nucleotide 1137 to 1160), GGTCAGCTTGCTATCTCGCAACTCG (nucleotide 1737 to 1761) and 
CTAAGGGTGGGGCTGATGCTGAA (nucleotide 845 to 867 on the complementary strand).
For sequencing of the S1 gene two PCR fragments were obtained and sequencing was performed 
with five different primers. RT-PCR products were thus obtained using either GCTATTGGTCGGATG 
(nucleotide 1 to 15) and ATTCCGATACCGCCGCTAACATCA (nucleotide 915 to 938 on the 
complementary strand) or a combination of GACTCTCAAGACGACTGTGTTTG (nucleotide 708 to 
730) and AGTGCCGCGGGGTGGTCTGATC (nucleotide1382 to 1403 on the complementary strand). 
Sequencing was performed with primers GCTATTGGTCGGATG (nucleotide 1 to 15), 
GACTCTCAAGACGACTGTGTTTG (nucleotide 708 to 730), 
ATGTTAGCGGCGGTATCGGAATGA (nucleotide 917 to 940), 
AGCTCTGCAAGTCCTGTCTCAAGT (nucleotide 345 to 368 on the complementary strand) and 
AGTGCCGCGGGGTGGTCTGATC (nucleotide 1382 to 1403 on the complementary strand).
Sequences used for comparisons were obtained from the NCBI database. Accession numbers of 
the reverse genetics clones used as reference sequence were ABP48922 (for σ3), ABP48917 (for μ1) 
and ABP48919 (for σ1).
3. Results
3.1. Production of a Vero cell-adapted virus (VeroAV)
Vero cells were infected with a laboratory stock of wild-type reovirus serotype 3 Dearing 
(T3/Human/Ohio/Dearing/55). Viral stocks used were first propagated in standard conditions of low  
multiplicity of infection (1 PFU/cell), or at a high multiplicity of infection, as described in Section 2. 
Such high-passage reovirus stocks resulting from serial propagation at a high multiplicity of infections 
are known to harbor a mixture of mutants and defective viruses and were used by various groups to 
facilitate establishment of viral persistence (Ahmed and Fields, 1982; Ahmed and Graham, 1977; 
Ahmed et al., 1980; Dermody et al., 1993). Using either of the two virus stocks, gradual cell death 
was observed in infected Vero cells with the presence of large cytoplasmic inclusions typical of 
reovirus infection (data not shown). However, a significant proportion of the cells remained alive in the
culture despite obvious viral-induced cytopathic effects. Cells infected with the high-passage stock of 
virus were maintained and propagated with occasional passage with trypsin. Cell death transiently 

































and gradually adapted until a cell culture presenting minimal cell death and cell growth 
indistinguishable from that of parental cells, was finally obtained. Analysis of virus produced by these 
cells was undertaken 21 weeks after the initial infection.
Cell-free supernatant was recovered and readily destroyed L929 cells, indicating the presence 
and release of infectious virus in the culture of Vero cells despite absence of apparent cytopathic effect 
at this time. Since this was not the purpose of the present study, the “persistently infected” Vero cells 
themselves were not further examined.
The Vero cell-adapted virus (VeroAV) was further propagated on L929 cells and viral titer was 
determined by plaque assay on Vero cells in the presence of chymotrypsin. VeroAV reaches titers 
similar to that of the wild-type virus under similar propagation conditions. The limiting dilution, 
TCID50 method was also used to determine virus titers on L929 cells using 96-multiwell plates (Danis 
and Lemay, 1993), The relative titers were between 1.3-fold lower to 1.9-fold higher by plaque assay 
for VeroAV compared to the wild-type virus. This small difference between the two methods could be 
explained, at least in part, by different plaque size for the two viruses as discussed in the following 
section.
3.2. Infectivity of VeroAV
Titration of infectious virus on Vero cells was initially performed in the presence of 
chymotrypsin, since wild-type virions are unable to form plaques on these cells in the absence of 
exogenous proteases (Brochu-Lafontaine and Lemay, 2012) (Fig. 1A); even under the microscope 
foci were very small in the absence of chymotrypsin and consisted of only few cells with incomplete 
lysis (Fig. 1B, panel a). This is consistent with the previous report showing that infection of Vero cells 
is relatively inefficient but that this blockage can be overcome by prior treatment with a protease, such 
as chymotrypsin, to generate ISVPs (Golden et al., 2002; Nygaard et al., 2012). Accordingly, large 
plaques were readily formed when chymotrypsin was added to the agar overlay used for viral titration 
(Fig. 1A and B), as previously described (Brochu-Lafontaine and Lemay, 2012). In contrast, VeroAV 
is able to bypass the restriction normally observed in Vero cells and forms plaques in the absence of 
chymotrypsin (Fig. 1A and B), while plaques formed by VeroAV in the presence of chymotrypsin were 
smaller than that observed with the wild-type virus (Fig. 1A and B).
The infection by the two viruses was then compared on a single infection cycle using detection of
































(Kim et al., 2010; Marcato et al., 2007); a commercially available antireovirus antibody directly 
conjugated to FITC, was used to facilitate the procedure, as previously used (Sandekian et al., 2013) 
and described in Section 2. In preliminary assays, the proportion of L929 cells infected with the wild-
type virus at a multiplicity of infection of 1 PFU/cell was approximately 50% compared to a theoretical
value of 63%, according to the Poisson distribution (data not shown). It thus appears that the procedure 
does adequately reflect the efficiency of viral infection. The efficiency of infection of VeroAV was then
compared with that of the wild-type virus; a representative experiment is presented on Fig.2. On Vero 
cells, in the absence of chymotrypsin, infection by the wild-type virus was very low compared to that 
on L929, the average of two different experiments indicated that infection was approximately fourfold 
more efficient in L929 cells while for VeroAV the difference was less than twofold between the two cell
lines. Addition of chymotrypsin on Vero cells increased infection of the wild-type virus by at least 
sixfold on average, consistent with results obtained by plaque assay. In contrast the effect of 
chymotrypsin on efficiency of VeroAV infection was at most twofold, indicating that the infection of 
Vero cells by VeroAV is largely independent of prior uncoating.
These results were further confirmed by immunoblotting analysis of the viral proteins 
synthesized during viral replication (Fig. 3). As expected, the addition of chymotrypsin to the medium 
allowed the wild-type virus to bypass the restriction while there was essentially no effect, under the 
same conditions, with VeroAV. In contrast, VeroAV was already able to efficiently infect Vero cells in 
the absence of chymotrypsin, as observed in both plaque assay and FACS-based analysis. On L929 
cells, VeroAV and wild-type virus were similar or even slightly better for VeroAV, as also previously 
observed by FACS.
3.3. Replicative ability of VeroAV
Virus titers produced upon one-cycle of replication in Vero cells were next examined (Fig. 4A). 
In the absence of chymotrypsin, VeroAV produced slightly more infectious virus than the wild-type 
virus. As expected, there was an increase in virus titer in the presence of chymotrypsin with the wild-
type confirming that infection by the wild-type virus is increased by prior uncoating of the virions. 
However, in the same conditions, VeroAV titer obtained was actually decreased, an observation that is 
reminiscent of the small plaques produced by this virus in the presence of chymotrypsin (Fig.1). The 
protocol was then modified by removal of the chymotrypsin 4 h post-infection (Fig.4B), allowing 

































viral particles. Under these conditions, wild-type virus titer was more than 100-fold higher when 
chymotrypsin was used, further indicating the positive effect of prior uncoating and indicating that the 
chymotrypsin had a negative effect on the infectivity of the released viral particles under these 
conditions of one-cycle viral replication. VeroAV titer remained higher than that of wild-type but was 
only slightly increased by chymotrypsin treatment, indicating that it is less dependent on prior 
uncoating for infection but more sensitive to the negative effects of chymotrypsin on released virions. 
When the experiment was repeated with a concentration of chymotrypsin reduced from 20 to 5 μg/ml, 
virus titer of the wild-type virus was significantly increased (more than 500-fold) while VeroAV titer 
was only increased fivefold (data not shown). Under these conditions, removal of chymotrypsin after 4 
h did not change the results. This further supports the idea that chymotrypsin increased infectivity of 
the wild-type virus but has only a limited, and even negative, effect on VeroAV. Again, this is probably 
reflected by the smaller plaque size observed with this virus in the presence of chymotrypsin (as shown
on Fig. 1).
Replicative ability of VeroAV also correlated with cytopathic effects observed upon infection 
(data not shown). In the absence of chymotrypsin, Vero cells were quite resistant to viral-induced 
cytopathic effect with the wild-type virus at a multiplicity of infection of 2 PFU/cell. In contrast, 
cytopathic effects were observed as early as 24 h post-infection with VeroAV and essentially all cells 
were destroyed by 48 h post-infection. When chymotrypsin was present, cytopathic effect was 
evidenced for both wild-type virus and VeroAV; cytopathic effect was already observed at 24 h post-
infection and essentially all cells were killed by 48 h.
3.4. Characterization of early events during infection by VeroAV
Since infection of Vero cells with the wild-type virus seems to rely on prior in vitro protease 
treatment, it was first suspected that the increased infectivity of VeroAV could be due to enhanced 
uncoating. This is normally accompanied by a reduced requirement for intracellular proteases during 
infection by virions and thus a reduced sensitivity to both inhibitors of lysosomal acidification, such as 
ammonium chloride (NH4Cl), or inhibitors of lysosomal uncoating proteases, such as E64 (Clark et 
al., 2006; Ebert et al., 2001). This was examined in L929 cells that have been extensively used in the 
literature for such studies. VeroAV and wild-type viruses exhibited a similar sensitivity to 5 mM 
NH4Cl, titers being reduced approximately 10-fold at this concentration (data not shown).This was 

































reduced 5 to 10-fold at the 50 μM concentration and between 30 to 50-fold at the 100 μM 
concentration, VeroAV thus being at least as sensitive as the wild-type virus. This suggests that the 
replication of VeroAV in the absence of chymotrypsin is not due to a reduced requirement for cysteine 
protease in the lysosomal compartment and that VeroAV is not an uncoating mutant.
3.5. Induction of, and resistance to, interferon by VeroAV
As mentioned in Section 1, Vero cells were chosen since, in addition to their limited ability to 
uncoat reovirus, they are also unable to produce interferon. Viruses could thus potentially lose their 
ability to control the interferon response, if this allows to gain other properties beneficial to viral  
maintenance and/or replication in Vero cells. Such viruses will be either more prone to induce 
interferon in interferon-competent cell lines, such as L929 mouse fibroblasts cells, or more sensitive to 
the antiviral action of interferon in these cells.
Induction of interferon was examined by measuring the antiviral effect of the supernatant from 
L929 cells infected with either the wild-type or VeroAV reovirus; the antiviral activity was measured 
against the unrelated encephalomyocarditis virus (EMCV), as previously described (Sandekian et al., 
2013). Supernatant from cells infected with either wild-type or VeroAV were both protective against 
EMCV. The undiluted supernatant recovered at 12 hours post-infection with each virus could decrease 
apparent EMCV titer from 5.4 X 10
9
 PFU/ml to 8.4 X 10
8
 for the wild-type virus and 7.4 X 10
8
 for 
VeroAV. Therefore, it does not appear that VeroAV could induce more interferon than the wild-type, 
parental, reovirus. This is also consistent with the presence of a proline at amino acid 208 of μ2 on both
the wild-type and VeroAV (data not shown), an amino acid position known to be responsible for 
differences in interferon induction between different reovirus strains (Irvin et al., 2012).
Sensitivity of VeroAV to interferon was next determined by TCID50 titration of parental wild-
type virus or VeroAV on murine L929 fibroblasts in the presence of 500 international units(IU)/ml of 
mouse β-interferon. At this high interferon concentration, virus titer was decreased by approximately 
6000-fold for the wild-type virus and more than 24,000-fold for VeroAV (data not shown), suggesting 
an increased sensitivity of the latter. The experiment was repeated at a lower interferon concentration 
(100 IU/ml)  and, under these conditions, VeroAV was clearly more sensitive, its titer being decreased 
by more than a thousandfold, while the wild-type virus titer was decreased only 15-fold (Fig. 6); 
VeroAV is thus essentially as sensitive as the “interferon-hypersensitive” P4L-12 mutant that was 

































3.6. Sequencing of viral genes encoding outer capsid proteins of VeroAV
Altogether, the three outer capsid proteins, σ1, σ3 and μ1, are responsible for virus binding and 
entry into host cells (most recently reviewed by: Danthi et al., 2010). In view of the previous results, 
indicating a decreased requirement of prior outer capsid removal for VeroAV infection of Vero cells, 
while the virus remained sensitive to inhibitors of intracellular outer capsid removal, the sequence of 
the genes encoding the three outer capsid proteins of VeroAV was determined. The original wild-type 
laboratory virus stocks, as well as the high-passage virus stock used to establish VeroAV-infected cells, 
were sequenced in parallel to better assess the significance of eventual amino acids substitutions in 
VeroAV.  Although there are certainly numerous mutants in the high-passage stock, there was no 
apparent differences with the original wild-type stock when PCR products were directly sequenced, 
reflecting the lack of selection of a new virus under these conditions. The sequences were also 
compared with the sequences reported for the genes of reovirus serotype 3 Dearing in the plasmids 
used for the generation of infectious virus by reverse genetics (Kobayashi et al., 2007).
The σ3 protein of VeroAV has no amino acid substitutions compared to the original virus that is 
also identical with the sequence of the reverse genetics clone; this absence of substitution in Vero AV 
contrasts with all known uncoating mutants but is consistent with the fact that VeroAV behaves 
differently from such mutants. In contrast, two amino acids substitutions were found in the σ1 protein 
of VeroAV compared with both the original wild-type virus and the reverse genetics virus, the Q78P 
and N198K substitutions. Three other substitutions (T249I, T408A and Y253S) were also found 
between wild-type and VeroAV on one hand, and the reverse genetics virus on the other hand. 
Comparisons with sequences in database are difficult due to extensive differences in σ1 protein when 
different serotypes are compared. Nevertheless, the T249I and T408A substitutions, compared to the  
sequence of the reverse genetics virus, were also found to be present in more than half the sequences of
type 3 viruses in the NCBI database; however, the Y253S substitution appears to be unique to the 
viruses used in the laboratory at the present time. 
The μ1 protein of VeroAV also exhibits two different amino acids substitutions compared to the 
original wild-type virus and to the reverse genetics virus, the E89G and A114V substitutions. These 
two amino acids are conserved between different mammalian reoviruses of all four serotypes present in
the NCBI database; two other differences between both the wild-type virus and VeroAV compared to 

































fact, observed more frequently than alanine at position 305 in sequences of all serotypes, the alanine at 
position 449 is conserved and A449T represents a novel variant of μ1 in the virus' laboratory stock.
4. Discussion
As with most viruses, reovirus' ability to infect different cell types and the final outcome resulting
from this infection, cell death or persistence establishment, has been mostly studied in one cell type, 
namely the L929 mouse fibroblasts. In the last few years, there has been a renewed interest to study  
reovirus replication and virus-host cell interactions. This is certainly largely due to current efforts to 
introduce the virus as an oncolytic agent. A better understanding of the virus' replication in different 
cell types could allow to better adapt the virus to specifically infect, replicate in, and kill cancer cells 
(Kim et al., 2007, 2011; Rudd and Lemay, 2005; Shmulevitz et al., 2012; van den Wollenberg et 
al., 2009, 2012).
As mentioned in Section 1, there has been relatively few detailed characterization of viruses 
adapted through persistence establishment; in the most-studied L929 cells model, there were many 
different amino acid substitutions on σ1, depending on the virus, and a single amino acid substitution 
on σ3 (Y354H). This last substitution was later shown to be most important and results in an increased 
ability of the virus to be uncoated (Dermody, 1998). Amino acids substitution in σ3 was most often 
observed in viruses recovered from other persistently infected cell lines although σ1 substitutions were 
also frequent, but the exact importance of these amino acids substitutions was not clearly established.  
(Kim et al., 2011). It should be mentioned that the sequence of the other genes, including that of the 
segment encoding the third outer-capsid protein, the μ1 protein, was not examined in this study. Virus 
persistence was also reported in CHO cells (Taber et al., 1976), MDCK cells (Montgomery et al., 
1991), SC1 feral mouse embryo fibroblasts (Danis et al., 1993) and Balb-3T3 mouse fibroblasts 
(Verdin et al., 1986) but detailed characterization of the resulting viruses is still lacking.
Vero cells chosen in the present study appeared relatively resistant to reovirus while efficiency 
was increased by prior chymotrypsin treatment resulting in uncoating of the virion. However, this could
be due to different factors in addition to a defect of uncoating in these cells that could be bypassed by 
prior removal of outer capsid protein σ3 and proteolytic cleavage of outer capsid μ1. An increased 
ability to bind onto sialic acid at the cell surface upon virion to ISVP proteolytic conversion could also 

































reviewed by: Danthi et al., 2010; Schelling et al., 2008). Finally, a change in the efficiency of final 
disassembly steps could lead to increased infectivity due to increased ability of the viral particles to 
cross the cellular, or endosomal, membrane.
Despite their relative resistance to reovirus, infected Vero cells gradually developed cytopathic 
effects and a significant cell death was observed. This was maintained for a long time before a balance 
was apparently established and cell death became inapparent in the culture of “persistently-infected” 
cells. Evolution of the cells was not studied further in this manuscript but the evolution of the virus was
evidenced by the apparent lack of remaining wild type sequence for either the σ1 or μ1 encoding gene 
in VeroAV. However, when individual clones were obtained from the PCR products and individually 
sequenced, amino acids substitutions in σ1 were consistently observed while the exact nature of amino 
acids changes in μ1 was variable (Table 2), although the two substitutions E89G and A114V were by 
far the most frequent. Interestingly, in a previous attempt to adapt the wild-type virus to Vero cells, the 
virus was collected after only 8 weeks; in this virus, the N198K substitution on σ1 was already found 
but not the Q78P while there was no substitution on μ1. This suggests that the N198K could be most 
important in the adaptation to Vero cells.
As previously mentioned, Vero cells possess two known interesting properties that may affect the 
nature of the virus recovered upon adaption to these cells. Vero cells lack the ability to produce 
interferon (Desmyter, et al., 1968; Emeny and Morgan, 1979), thus likely making them more 
susceptible to reovirus replication and propagation once they are infected. They also exhibit a reduced 
ability to uncoat the virus, thus probably limiting initial entry steps. It is thus expected that the virus 
will evolve toward an increased ability to initiate viral infection. Surprisingly, in contrast to classical 
uncoating mutants, VeroAV was sensitive to the inhibitor of cysteine protease and, accordingly, the σ3 
protein did not show an altered sequence. This contrast with the situation observed with viruses 
recovered from persistently-infected murine SC1 cells; although these cells are also deficient in 
interferon response (Danis et al., 1997) and ability to uncoat the virus (unpublished data), an amino 
acids substitution in the outer lobe of the σ3 protein was observed in that case (Table 1). In all other 
reports of viral isolates from persistently-infected cells, an amino acid substitution in σ3 was also 
observed, although substitutions in σ1 were also often found (Table 1).
The available crystal structure of the σ3-μ1 heterohexamer that forms the bulk of the outer capsid
(Liemann et al., 2002) and the high-resolution structure of the virion by electron cryomicroscopy 

































zone between neighboring heterohexamers at their basis in the most inner part of the outer capsid (Fig. 
6) while the A114 position is located at a position suggesting a possible effect on the interaction 
between the three μ1 molecules of each heterohexamer (Fig. 7). Either one, or both, of these changes 
could alter outer capsid stability and/or disassembly; interestingly, amino acids substitutions that affect 
the stability of the σ3-μ1 heterohexamer were previously observed in these regions (Agosto et al., 
2007; Middleton et al., 2007), including one of E89 that appears to render the virus thermolabile and 
thus potentially destabilizes the capsid and favors virus entry and disassembly under normal 
temperature conditions. The amino acids substitutions in μ1 are thus likely responsible for the changes 
in sensitivity of VeroAV to chymotrypsin, as reflected in reduced plaque size. The interaction between 
σ3 and μ1 appears to be essential in the control of the function of these two proteins when they are 
under their free form in the cytoplasm (reviewed by: Schiff, 1998; 2008). The σ3 protein is believed to 
inhibit the dsRNA dependent protein kinase (PKR) activation due to its ability to bind the double-
stranded RNA (dsRNA) activator of PKR (Beattie et al., 1995; Giantini and Shatkin, 1989; Imani 
and Jacobs, 1988; Lloyd and Shatkin, 1992; Yue and Shatkin, 1997), an ability that is lost upon its 
interaction with μ1 (Huismans and Joklik, 1976; Lemieux et al., 1987); this is likely one important 
factor that could affect virus' sensitivity to interferon (reviewed by: Samuel, 1998; Sherry,  2009). 
Accordingly, the PKR inhibition and resulting effect on host translation is likely dependent on the 
relative level of free σ3 compared to μ1-bound σ3 (Schmechel et al., 1997). Reciprocally, the μ1-
induced apoptosis is increased in absence of σ3 (Coffey et al., 2006). Numerous strands of evidence 
indicate that dsRNA and μ1 binding by σ3 are mutually exclusive (Bergeron et al., 1998; Huismans 
and Joklik, 1976; Lemieux et al., 1987; Liemann et al., 2002; Shepard et al., 1996) Increased 
sensitivity of VeroAV to interferon, in absence of any change in interferon induction, is thus consistent 
with the idea that a change in the efficiency of heterohexamers formation, resulting from amino acids 
substitutions in μ1, can indirectly affect the control of PKR by σ3 and, therefore, virus' sensitivity to 
interferon.
The contact regions between μ1 in neighboring heteroxamers are also similar to the contact 
regions between μ1 and λ2 forming the turret through which σ1 trimers are anchored and exposed at 
the virion's surface (Liemann et al., 2002; Middleton et al., 2007; Zhang et al., 2005; ). The nature 
of the μ1 protein could thus indirectly affect the association and exposure of σ1 at the virion's surface. 
Interestingly, it was recently suggested that amino acids changes in λ2 itself could affect the function of

































et al., 2012). It should also be remembered that σ1 and μ1 are involved in binding and entry steps in 
viral infection, and it is thus somehow expected that these two phenomena need to be well adapted to 
each other. Accordingly, a role of μ1 in a σ1-determined phenotype was also previously observed in 
different contexts, such as apoptosis, neurovirulence or development of oily fur syndrome (Clarke et 
al., 2001; Derrien et al., 2003; Hrdy et al., 1982; Rodgers et al., 1997; Tyler et al., 1996). 
Interestingly, in a Vero cell-adapted avian reovirus, gene reassortment experiments assigned the 
adaptive changes to both the σC cell-binding moieties homologous to σ1 and the μB major outer capsid
protein homologous to μ1 (Meanger et al., 1999). This further supports the idea that these two proteins
functionally interact and are essential in virus' adaption to Vero cells.
Interestingly, although the asparagine-198 of σ1 is not directly involved in the binding to sialic 
acid, it was previously shown that its substitution by an acidic amino acid (N198E) does prevent  
binding (Chappell et al., 1997; Dermody et al., 1990; Reiter et al., 2011). It is thus possible that 
substitution by a basic amino acid, as in VeroAV (N198K), could rather positively influence this 
binding and could be responsible for better infectivity on Vero cells.
In the last few years, a powerful plasmid-based reverse genetics approach has been introduced for
the study of mammalian reovirus (Kobayashi et al., 2007; reviewed by: Boehme et al., 2011; van den
Hengel et al., 2013; Lemay, 2011). This approach could be envisaged in the future to determine the 
respective roles of σ1 and μ1 amino acids substitution of VeroAV in increased infectivity in Vero cells 
and increased sensitivity to interferon. However, it cannot be excluded that these properties cannot be 
separately attributed to one of the two genes and that single amino acids substitutions will not be 
compatible in the wild type virus genetic background, especially that encoded by the plasmids of the 
reverse genetics systems.
Altogether, the work described herein is a good illustration that reovirus infection and replication 
need to be further investigated in cell types that differ from the traditionally used models. Clearly, 
selection of novel viruses during viral persistence is more complex than selecting for σ3 proteins that 
are more susceptible to uncoating proteases. The use of heterogeneous viral populations that can be 
adapted to different cells or different conditions thus remains a powerful approach to identify novel 
viral adaptations that could be of interest in the development of reovirus as a virotherapy agent. 
Although we do not have evidence that this particular virus (VeroAV) has a superior oncolytic activity, 
it was recently shown (Shmulevitz et al., 2012) that selection of large-plaque variants on L929 cells, as

































to pursue the characterization of VeroAV in cancer cell lines. In the future, long-term adaptations of 
reovirus to cells harboring well-defined genetic alterations in cellular immortalization/transformation 
pathways could become a powerful approach to better evaluate critical host-cell properties for optimal 
reovirus replication, propagation, and host-cell killing. In addition to such well-defined cellular models,
human cancer cell lines could be used to select novel reovirus for an optimal oncolytic effect in 
different tumor cell types. 
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Fig. 1. Plaque formation by VeroAV. Plaque assay was performed on Vero cells in the presence (Cht.) 
or absence (Cont.) of chymotrypsin, as described in Section 2.  (A) A single well presenting well-
separated plaques, in the presence or absence of chymotrypsin using the same amount of virus 
inoculum, are presented for the wild-type virus and VeroAV. Cell monolayers were fixed and stained at 
either 5 days post-infection in the absence of chymotrypsin or 4 days post-infection when chymotrypsin
was present. Arrows point to representative plaques observed for the wild-type virus in the presence of 
chymotrypsin and for VeroAV in absence and presence of chymotrypsin. (B) Closer examination of 
stained plaques was done under an inverted microscope using a low magnification, 4X, objective; 
arrows point to representative plaques in panel a and d. Bar is 0.5 mm.
Fig.2. Efficiency of infection by VeroAV determined by FACS analysis. Vero cells (panel A and B) or 
L929 cells (panel C) were infected at a MOI of 5 with either wild-type virus (WT) or VeroAV, as 
indicated. The cells were recovered 24 h post-infection and analyzed by FACS for detection of 
intracellular reovirus antigens, as described in Section 2. Mock-infected cells were similarly processed 
and incubated with the fluorescent antibody (filled in pale grey). In panel B, chymotrypsin was added 
for infection of Vero cells, as described in Section 2.
Fig.3. Synthesis of viral protein in VeroAV-infected cells. Vero cells or L929 cells were infected with 
either wild-type virus (WT) or VeroAV at a MOI of 5, as indicated. Proteins were recovered at 24 h 
post-infection and analyzed for the presence of viral proteins by immunoblotting, as described in 
Section 2; positions of the two major outer capsid proteins, ơ3 and μ1C, are indicated.
Fig.4. Production of infectious virus in VeroAV-infected cells. Vero cells were infected with either 
wild-type or VeroAV at a MOI of 5 in the presence (dark bar) or absence of 20 μg/ml of chymotrypsin, 
frozen 24 hours post-infection and virus titers were determined (panel A). In panel B, the same 
experiment was performed except that medium was changed 4 hours post-adsorption to remove 
chymotrypsin and heat-inactivated fetal bovine serum was added.

































type or VeroAV at a MOI of 2 in the absence or presence of E64 at a concentration of 50 or 100 μM, as 
indicated. Infected cells were frozen 24 hours post-infection and virus titers were determined. Results 
are presented as the average of two separate experiments, error bars represent standard error of the 
mean.
Fig.6. Sensitivity of VeroAV to interferon. L929 cells were used to titer the wild-type parental reovirus,
VeroAV or the interferon-hypersensitive P4L-12 isolate, using serial tenfold dilution in the TCID 50
method, in the absence or presence of murine β-interferon at 100 international units(IU)/ml, as
described in Section 2.
Fig.7. Positions of amino acids substitutions on μ1 structure. The structure the two adjacent μ1 trimers 
is presented from below with arrows pointing at the position of E89 and A114 amino acids harboring 
substitutions on VeroAV; figure adapted from Zhang et al., 2005, with permission from Elsevier.
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